Last reviewed 2026-04-22 · How we verify

Brivaracetam Film-coated tablet

Brivaracetam Film-coated tablet is a Antiepileptic agent (SV2A ligand) Small molecule drug developed by UCB Biopharma SRL. It is currently in Phase 3 development for Adjunctive treatment of partial-onset seizures in patients with epilepsy, Adjunctive treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy.

Brivaracetam binds to synaptic vesicle protein 2A (SV2A) in the brain to reduce neuronal excitability and prevent seizures.

Brivaracetam binds to synaptic vesicle protein 2A (SV2A) in the brain to reduce neuronal excitability and prevent seizures. Used for Adjunctive treatment of partial-onset seizures in patients with epilepsy, Adjunctive treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy.

At a glance

Mechanism of action

Brivaracetam is a high-affinity ligand for SV2A, a protein involved in synaptic vesicle trafficking and neurotransmitter release. By binding to SV2A, it modulates neuronal activity and reduces the propensity for seizure generation. This mechanism is similar to levetiracetam but with higher selectivity and potency for SV2A.

Approved indications

• Adjunctive treatment of partial-onset seizures in patients with epilepsy
• Adjunctive treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy

Common side effects

• Somnolence
• Fatigue
• Dizziness
• Headache
• Irritability
• Nausea

Key clinical trials

• A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (PHASE3)
• A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (PHASE3)
• A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy (PHASE3)
• A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization (PHASE3)
• A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects (PHASE1)
• Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures (PHASE3)
• Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Brivaracetam Film-coated tablet CI brief — competitive landscape report
• Brivaracetam Film-coated tablet updates RSS · CI watch RSS
• UCB Biopharma SRL portfolio CI

Frequently asked questions about Brivaracetam Film-coated tablet

Related

• Drug class: All Antiepileptic agent (SV2A ligand) drugs
• Target: All drugs targeting SV2A (synaptic vesicle protein 2A)
• Manufacturer: UCB Biopharma SRL — full pipeline
• Therapeutic area: All drugs in Neurology
• Indication: Drugs for Adjunctive treatment of partial-onset seizures in patients with epilepsy
• Indication: Drugs for Adjunctive treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy
• Compare: Brivaracetam Film-coated tablet vs similar drugs
• Pricing: Brivaracetam Film-coated tablet cost, discount & access